DUBLIN--(BUSINESS WIRE)--The "Wound Care Biologics Market by Product (Biological Skin Substitutes (Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User (Hospitals, Burn Centers) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The wound care biologics market is expected to reach USD 2.26 billion by 2023 from USD 1.42 billion in 2018, at a CAGR of 9.8%
Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.
Based on product, the wound care biologics market is segmented into biologic skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share in 2018 and grow at the highest rate from 2018 to 2023.
The rising incidence of hard-to-heal wounds and their growing adoption (due to their high efficacy) are driving the growth of this product segment. The biological skin substitutes segment is further categorized into human donor tissue-derived products, acellular animal-derived products, and biosynthetic products.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Wound Care Biologics Market, By Product
7 Wound Care Biologics Market, By Wound Type
8 Wound Care Biologics Market, By End User
9 Wound Care Biologics Market, By Region
10 Competitive Landscape
11 Company Profiles
- Anika Therapeutics
- Integra Lifesciences
- Marine Polymer Technologies
- Mimedx Group
- Mlnlycke Health Care AB (Investor AB)
- Osiris Therapeutics
- Smith & Nephew
- Solsys Medical
- Wright Medical
For more information about this report visit https://www.researchandmarkets.com/research/66lw4r/wound_care?w=4